Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04976803 · ClinicalTrials.gov registry record
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
A clinical trial of Solid Tumor, Unspecified, Adult, sponsored by Artios Pharma.
- Completed
- Registry status
- 229
- Enrollment target
- 3
- Study locations
NCT04976803: Completed study of Solid Tumor, Unspecified, Adult, sponsored by Artios Pharma.
NCT04976803 is a study of Solid Tumor, Unspecified, Adult that has completed, run by Artios Pharma. The registered enrollment target is 229 participants, above the 146-participant average among 6 other Solid Tumor, Unspecified, Adult trials with a reported enrollment target (57% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04976803, a study of Solid Tumor, Unspecified, Adult, has completed, sponsored by Artios Pharma.
- COMPLETED
- Registry status
- 229 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
Primary Outcome
ATM protein expression levels from tumor tissue assessed by immunohistochemistry (IHC)
Conditions Studied
Interventions
- OTHER Determination of ATM alteration status.
Study Locations (3)
Oklahoma
- Oklahoma University - Oklahoma City
Tennessee
- Tennessee Oncology - Nashville
Other
- Sarah Cannon Research UK - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2022-06-30 |
What the finished NCT04976803 record still lists
NCT04976803 is an observational study that tracks outcomes without assigning an intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, above the 146-participant average among 6 other Solid Tumor, Unspecified, Adult trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Solid Tumor, Unspecified, Adult appearing as the primary indexed condition, and to 1 intervention - of which Determination of ATM alteration status. is the first listed.
NCT04976803 reports a single indexed study location in Oklahoma, Tennessee, Other.
Frequently Asked Questions
What is clinical trial NCT04976803 about?
NCT04976803 is a clinical study titled "Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein". This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
What is the current status of trial NCT04976803?
This trial is currently completed. The enrollment target is 229 participants. The study started on 2021-05-28. Estimated completion is 2022-06-30.
What conditions does trial NCT04976803 study?
This clinical trial studies the following conditions: Solid Tumor, Unspecified, Adult.
What interventions are being tested in trial NCT04976803?
The interventions under investigation include: Determination of ATM alteration status. (OTHER).
Who is sponsoring clinical trial NCT04976803?
This trial is sponsored by Artios Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04976803 being conducted?
This trial has 3 study locations across Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Unspecified, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
RECRUITING · NA
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Psychotherapy Intervention for Latinos With Adv Cancer
RECRUITING · NA
-
Psychotherapy Intervention for Latinos With Advanced Cancer
RECRUITING · NA
-
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
COMPLETED · Phase 1
-
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI